Compass Therapeutics: Key Clinical and Financial Catalysts Approaching

The clinical development pipeline at Compass Therapeutics is set to reach several significant inflection points this year. The biopharmaceutical company’s valuation could be substantially impacted by progress with its lead oncology candidates, Tovecimig and CTX-8371. A central question for investors is whether the firm can translate its initial, targeted successes into positive outcomes within broader clinical trials.

Compass Therapeutics enters this pivotal period from a position of financial strength. The company reported cash and equivalents of approximately $209 million as of the end of 2025, which management believes provides an operating runway extending into 2028. This robust balance sheet affords the flexibility to advance new projects, including CTX-10726, a candidate for which a Phase 1 study is slated to commence before the end of the first quarter of 2026.

Supporting this next phase, the company strengthened its executive team effective January 1st. Arjun Prasad joined as Chief Commercial Officer, focusing on future market strategy, while Cynthia Sirard was appointed Chief Medical Officer to oversee clinical development. Initial data from the CTX-10726 study is anticipated in the latter half of 2026.

Should investors sell immediately? Or is it worth buying Compass Therapeutics?

CTX-8371 Gains Momentum and Expands Scope

Notable advances have been reported for CTX-8371, a bispecific antibody. Following an additional confirmed treatment response in a patient with Hodgkin lymphoma, Compass Therapeutics is exploring pathways for an accelerated regulatory approval process. Concurrently, the company is broadening its clinical investigation. New patient cohorts are now being recruited to evaluate the drug’s efficacy in treating triple-negative breast cancer and non-small cell lung cancer. This strategic move marks a deliberate expansion of CTX-8371’s application into major solid tumor indications.

Anticipated Milestones for Tovecimig

All eyes are on Tovecimig, another bispecific antibody candidate targeting advanced cholangiocarcinoma (bile duct cancer). Top-line results from the Phase 2/3 COMPANION-002 study are expected by the end of March. Given the limited treatment options currently available for this aggressive cancer, the market will scrutinize the survival rate data closely. The candidate has already demonstrated clinical activity in a separate study, with data presented in January showing a response in heavily pre-treated patients with colorectal cancer.